Cholesteryl ester - PDFSEARCH.IO - Document Search Engine

Cholesteryl ester
Results: 27

#	Item
11	SYNAGEVA BIOPHARMA™ HIGHLIGHTS SEBELIPASE ALFA AND LAL DEFICIENCY DATA AT THE LYSOSOMAL DISEASE NETWORK (LDN) WORLD SYMPOSIUM™ LEXINGTON, Mass., February 13, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), Add to Reading List Source URL: www.synageva.com Language: English - Date: 2014-02-13 14:27:52 Medicine Lysosomal Acid Lipase Deficiency Wolman disease Cholesteryl ester storage disease Lysosomal storage disease Hunter syndrome Low-density lipoprotein Mucopolysaccharidosis Cirrhosis Health Rare diseases Lipid storage disorders
12	SYNAGEVA BIOPHARMA™ HIGHLIGHTS SBC-103 DATA AT THE LYSOSOMAL DISEASE NETWORK (LDN) WORLD SYMPOSIUM™ LEXINGTON, Mass., February 12, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical compan Add to Reading List Source URL: www.synageva.com Language: English - Date: 2014-02-12 15:27:02 Syndromes Sanfilippo syndrome Wolman disease Mucopolysaccharidosis Cholesteryl ester storage disease Lysosomal storage disease Hunter syndrome Blood–brain barrier Health Rare diseases Lipid storage disorders
13	SYNAGEVA BIOPHARMA™ REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS LEXINGTON, Mass., July 30, [removed]Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products Add to Reading List Source URL: www.synageva.com Language: English - Date: 2014-08-04 12:07:09 Lysosomal Acid Lipase Deficiency Wolman disease Cholesteryl ester storage disease Mucopolysaccharidosis Hunter syndrome Health Rare diseases Lipid storage disorders
14	SYNAGEVA BIOPHARMA™ ISSUED U.S. PATENT FOR TREATMENT OF LAL DEFICIENCY LEXINGTON, Mass., March 4, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products Add to Reading List Source URL: www.synageva.com Language: English - Date: 2014-03-04 08:05:19 Lysosomal Acid Lipase Deficiency Wolman disease Cholesteryl ester storage disease Lysosomal storage disease Mucopolysaccharidosis Sanfilippo syndrome Acid lipase disease Wolman Rare diseases Health Lipid storage disorders
15	SYNAGEVA BIOPHARMA™ REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LAL DEFICIENCY Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Di Add to Reading List Source URL: www.synageva.com Language: English - Date: 2014-10-09 07:26:12 Medicine Cardiology Lipoproteins Lysosomal Acid Lipase Deficiency Clinical research Cholesteryl ester storage disease Wolman disease Niacin Clinical trial Health Rare diseases Lipid storage disorders
16	SYNAGEVA BIOPHARMA™ ANNOUNCES SATELLITE SYMPOSIUM AT THE NATIONAL LIPID ASSOCIATION MEETING LEXINGTON, Mass., May 2, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing the Add to Reading List Source URL: www.synageva.com Language: English - Date: 2014-05-02 07:29:47 Wolman disease Cholesteryl ester storage disease Sanfilippo syndrome Mucopolysaccharidosis Lysosomal storage disease Lysosomal Acid Lipase Deficiency Health Rare diseases Lipid storage disorders
17	LAL DEFICIENCY DISEASE REVIEW PUBLISHED IN ATHEROSCLEROSIS LEXINGTON, Mass., April 21, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare dise Add to Reading List Source URL: www.synageva.com Language: English - Date: 2014-04-21 08:00:38 Medicine Lysosomal Acid Lipase Deficiency Wolman disease Cholesteryl ester storage disease Lysosomal storage disease Acid lipase disease Mucopolysaccharidosis Sanfilippo syndrome Lysosomal lipase Health Rare diseases Lipid storage disorders
18	SYNAGEVA’S SEBELIPASE ALFA RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR EARLY ONSET LAL DEFICIENCY FROM THE U.S. FOOD AND DRUG ADMINISTRATION LEXINGTON, Mass., May 20, [removed]Synageva BioPharma Corp. (Synageva) (NASD Add to Reading List Source URL: www.synageva.com Language: English - Date: 2013-05-20 07:13:10 Wolman disease Lysosomal Acid Lipase Deficiency Cholesteryl ester storage disease Lysosomal storage disease Mucopolysaccharidosis Sanfilippo syndrome Wolman Acid lipase disease Lysosomal lipase Health Rare diseases Lipid storage disorders
19	SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA AT THE NASPGHAN MEETING LEXINGTON, Mass., October 11, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare Add to Reading List Source URL: www.synageva.com Language: English - Date: 2013-10-11 07:24:04 Lipid storage disorders Lysosomal Acid Lipase Deficiency Wolman disease Cholesteryl ester storage disease Sanfilippo syndrome Lysosomal storage disease Hunter syndrome Enzyme replacement therapy Mucopolysaccharidosis Health Medicine Rare diseases
20	The diagnosis and management of nonalcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Add to Reading List Source URL: www.naspghan.org Language: English - Date: 2014-06-18 12:24:49 Hepatitis Histopathology Non-alcoholic fatty liver disease Diabetes Fatty liver Steatohepatitis Alcohol abuse Cholesteryl ester storage disease Cirrhosis Medicine Health Hepatology

UPDATE